Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Pharm ; 397(1-2): 225-30, 2010 Sep 15.
Article in English | MEDLINE | ID: mdl-20637849

ABSTRACT

To develop a novel sibutramine base-loaded solid dispersion with enhanced solubility and bioavailability, various solid dispersions were prepared using a spray drying technique with hydrophilic polymers such as gelatin, HPMC and citric acid. Their solubility, thermal characteristics and crystallinity were investigated. The dissolution and pharmacokinetics of the sibutramine base-loaded solid dispersion were then compared with a sibutramine hydrochloride monohydrate-loaded commercial product (Reductil). The solid dispersions prepared with gelatin gave higher drug solubility than those prepared without gelatin, irrespective of the amount of polymer. The sibutramine base-loaded solid dispersions containing hydrophilic polymer and citric acid showed higher drug solubility compared to sibutramine base and sibutramine hydrochloride monohydrate. Among the formulations tested, the solid dispersion composed of sibutramine base/gelatin/HPMC/citric acid at the weight ratio of 1/0.8/0.2/0.5 gave the highest solubility of 5.03+/-0.24 mg/ml. Our DSC and powder X-ray diffraction results showed that the drug was present in an altered amorphous form in this solid dispersion. The difference factor (f(1)) values between solid dispersion and commercial product were 2.82, 6.65 and 6.31 at pH 1.2, 4.0 and 6.8, respectively. Furthermore, they had the similarity factor (f(2)) value of 65.68, 53.43 and 58.97 at pH 1.2, 4.0 and 6.8, respectively. Our results suggested that the solid dispersion and commercial product produced a similar correlation of dissolution profiles at all pH ranges. The AUC, C(max) and T(max) of the parent drug and metabolite I and II from the solid dispersion were not significantly different from those of the commercial product, suggesting that the solid dispersion might be bioequivalent to the commercial product in beagle dogs. Thus, the sibutramine base-loaded solid dispersion prepared with gelatin, HPMC and citric acid is a promising candidate for improving the solubility and bioavailability of the poorly water-soluble sibutramine base.


Subject(s)
Anti-Obesity Agents/pharmacokinetics , Cyclobutanes/pharmacokinetics , Animals , Anti-Obesity Agents/blood , Anti-Obesity Agents/chemistry , Area Under Curve , Biological Availability , Chemical Phenomena , Cyclobutanes/blood , Cyclobutanes/chemistry , Desiccation , Dogs , Drug Carriers , Gelatin , Hypromellose Derivatives , Male , Methylcellulose/analogs & derivatives , Polymers/chemistry , Powders , Solubility
2.
J Pharm Pharmacol ; 62(4): 448-55, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20604833

ABSTRACT

OBJECTIVES: The aim of this study was to develop a novel itraconazole-loaded gelatin microcapsule without ethanol with enhanced oral bioavailability. METHODS: Various gelatin microcapsules were prepared using a spray-drying technique. Their physicochemical properties, dissolution, characteristics and pharmacokinetics in rats were evaluated and compared with those of a commercial product. KEY FINDINGS: The gelatin microcapsule at a weight ratio for itraconazole/gelatin/citric acid of 1 : 3 : 0.3 was spherical in shape with a smooth surface and inner hole, and gave a maximum drug solubility of about 700 microg/ml. The gelatin microcapsule dramatically increased the initial dissolution rate of itraconazole compared with a commercial product in simulated gastric fluids (pH 1.2). Moreover, at the same dose as the commercial product, it gave significantly higher initial plasma concentrations, C(max) and AUC of itraconazole in rats than did the commercial product, indicating that providing the drug in the gelatin microcapsule caused enhanced absorption in rats. At half dose, it gave similar AUC, C(max) and T(max) values to the commercial product, suggesting that it was bioequivalent to the commercial product in rats. CONCLUSIONS: The itraconazole-loaded gelatin microcapsule without ethanol developed using a spray-drying technique at half the dose of the commercial product can deliver itraconazole in a pattern that allows fast absorption in the initial phase, making it bioequivalent to the commercial product.


Subject(s)
Capsules , Drug Carriers/chemistry , Itraconazole/pharmacokinetics , Technology, Pharmaceutical/methods , Administration, Oral , Animals , Area Under Curve , Biological Availability , Chemistry, Pharmaceutical/methods , Citric Acid , Gastric Juice , Gelatin , Hydrogen-Ion Concentration , Intestinal Absorption , Itraconazole/blood , Itraconazole/chemistry , Male , Rats , Rats, Sprague-Dawley , Solubility
3.
Int J Pharm ; 395(1-2): 161-6, 2010 Aug 16.
Article in English | MEDLINE | ID: mdl-20580799

ABSTRACT

Three solid dispersions containing poorly water-soluble tacrolimus were prepared with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and dioctyl sulfosuccinate (DOSS) using a spray-drying technique via the solvent-evaporation method with a methylene chloride/ethanol mixture, the solvent-wetting method with ethanol and the surface-attached method with water, respectively. The solubility and dissolution of the drug in the three solid dispersions were evaluated compared to drug powder. Furthermore, their physicochemical properties were investigated using SEM, DSC and powder X-ray diffraction. The solubility and dissolution of the drug were significantly improved in the order of the tacrolimus-loaded solid dispersion prepared by: solvent-evaporation method>solvent-wetting method>surface-attached method. The solid dispersions prepared by solvent evaporation appeared as an aggregated form with the amorphous form. In particular, the solid dispersion prepared by the solvent-evaporation method improved solubility about 900-fold and dissolution of tacrolimus 15-fold because of its reduced particle size, increased surface area and close contact between the hydrophilic carrier and the drug. In the solvent-wetting method, the drug, which was changed to an amorphous form, was attached onto the surface of undissolved carriers. However, the solid dispersion prepared by the surface-attached method gave an unchanged crystalline form. In this solid dispersion, the carriers were attached to the surface of the undissolved drug, resulting in changing the drug from being hydrophobic to hydrophilic. As the crystal form of drug in this solid dispersion was not converted to the amorphous form unlike other solid dispersions, it gave relatively less solubility and dissolution of the drug than did the others. Thus, in the development of a solid-dispersion system containing poorly water-soluble drugs, the method of preparation plays an important role in the solubility and crystallinity of the drugs.


Subject(s)
Immunosuppressive Agents/chemistry , Tacrolimus/chemistry , Technology, Pharmaceutical/methods , 2-Hydroxypropyl-beta-cyclodextrin , Calorimetry, Differential Scanning , Chemistry, Pharmaceutical , Crystallization , Crystallography, X-Ray , Dioctyl Sulfosuccinic Acid/chemistry , Drug Carriers , Drug Compounding , Ethanol/chemistry , Hydrophobic and Hydrophilic Interactions , Kinetics , Methylene Chloride/chemistry , Microscopy, Electron, Scanning , Powder Diffraction , Powders , Solubility , Solvents/chemistry , Surface Properties , Water/chemistry , beta-Cyclodextrins/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL